# ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

> **NCT07673627** · PHASE2 · RECRUITING · sponsor: **argenx** · enrollment: 40 (estimated)

## Conditions studied

- AChR-Ab Seropositive Generalized Myasthenia Gravis
- Myasthenia Gravis (MG)
- MG - Myasthenia Gravis
- gMG

## Interventions

- **BIOLOGICAL:** Empasiprubart IV
- **OTHER:** Placebo IV
- **COMBINATION_PRODUCT:** Efgartigimod PH20 SC PFS

## Key facts

- **NCT ID:** NCT07673627
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-10
- **Primary completion:** 2027-10
- **Final completion:** 2028-04
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07673627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07673627, "ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07673627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*